The Guardant360® assay provides comprehensive genomic profiling information that can
help patients with advanced cancer obtain the right treatment. The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster.
Our solutions for patients with cancer are enabled by Guardant Health’s proprietary Digital Sequencing technology. We combined robust, high-efficiency biochemistry at the front-end, with next-generation sequencing and a machine-learning augmented bioinformatics pipeline, to create a platform we believe delivers the clinical sensitivity levels necessary for best-in-class products today and tomorrow across all stages of cancer.